What is the best first choice oral drug therapy for OAB?
Neurourology and Urodynamics · 2024-08 · 43 (6) · 1328-1336
DOI: 10.1002/nau.25397 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neurourology and Urodynamics, online erschienen am 25.01.2024. Verfasst von Arun Sahai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Guy's Hospital & King's College, London, UK. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Muscarinic Antagonists, Adrenergic beta-3 Receptor Agonists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Aims
The management of overactive bladder (OAB) involves lifestyle changes and conservative measures in the first instance with the use of liquid/dietary advice, weight loss, and bladder training. Thereafter oral pharmacotherapy is instigated in symptomatic patients. Antimuscarinics and beta 3 agonists form the main classes of drug therapy in this field. Views on what is the best first line OAB treatment is changing based on recent evidence and adverse event profiles of these medications.
Methods
At the ICI‐RS meeting 2023, Bristol, UK this topic was discussed and debated as a proposal. The following article summarizes the concepts presented that day as well as the interactive discussion that took place thereafter.
Results
OAB guidelines are moving in many circumstances to an either antimuscarinic or beta 3 agonist approach based on patient factors. Several studies have raised concerns on the long‐term impact of antimuscarinics, in relation to cognition, dementia, cardiovascular events, and mortality all related to antimuscarinic load. Neither antimuscarinics nor beta 3 agonists have good persistence and adherence rates in the medium to long term. Several barriers also exist to prescribing including guidelines recommending utilizing drugs with the lowest acquisition cost and “step therapy.” A newer approach to managing OAB is personalized therapy in view of the many possible etiological factors and phenotypes. These concepts are highlighted in this article.
Conclusions
Current oral pharmacotherapy in managing OAB is limited by adverse events, adherence and persistence problems. Both antimuscarinics and beta 3 agonists are efficacious but most clinical trials demonstrate significant placebo effects in this field. Personalizing treatment to the individual seems a logical approach to OAB. There is a need for better treatments and further studies are required of existing treatments with high quality longer term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Guy's Hospital & King's College, London, UK.
- Department of Urogynaecology, King's College Hospital & King's College, London, UK.
- Bristol Urological Institute, Southmead Hospital, Bristol, UK.
- University of Bristol, Bristol, UK.
- Desai Sethi Urology Institute, University of Miami Miller School of medicine, Miami, Florida, USA.
- University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Zitieren
APA
Sahai, A., Robinson, D., Abrams, P., Wein, A., & Malde, S. (2024). What is the best first choice oral drug therapy for OAB?. Neurourology and Urodynamics, 43(6), 1328-1336. https://doi.org/10.1002/nau.25397
Vancouver
Sahai A, Robinson D, Abrams P, Wein A, Malde S. What is the best first choice oral drug therapy for OAB?. Neurourology and Urodynamics. 2024;43(6):1328-1336. doi:10.1002/nau.25397
BibTeX
@article{Sahai2024,
author = {Sahai, Arun and Robinson, Dudley and Abrams, Paul and Wein, Alan and Malde, Sachin},
title = {What is the best first choice oral drug therapy for OAB?},
journal = {Neurourology and Urodynamics},
year = {2024},
volume = {43},
number = {6},
pages = {1328--1336},
doi = {10.1002/nau.25397}
}
EUVIMED